The Sleep-Alzheimer's Connection:

How Nighttime Brain Cleansing May Hold Keys to Treatment

The human brain performs a remarkable feat each night: it washes itself. During sleep, cerebrospinal fluid pulses through brain tissue in rhythmic waves, flushing out metabolic waste products that accumulate during waking hours. Among these waste products is beta-amyloid, the protein that forms the hallmark plaques of Alzheimer's disease. This nocturnal housekeeping system, scientists increasingly believe, may be central to understanding—and potentially treating—the most common form of dementia.

The relationship between sleep disruption and Alzheimer's disease has long been observed but poorly understood. Now, a convergence of research from neuroscience, molecular biology, and clinical medicine is revealing that this connection runs deeper than anyone suspected. The findings suggest that sleep disturbances are not merely a symptom of Alzheimer's but may be a contributing cause—and that interventions targeting sleep could offer new avenues for prevention and treatment.

---

SIDEBAR: Diagnosing Alzheimer's in Life—And Why It Matters

The Evolution from Autopsy to Living Diagnosis

Alzheimer's disease could once only be definitively diagnosed after death through autopsy examination of brain tissue. For decades, physicians could only make a "probable Alzheimer's disease" diagnosis based on clinical symptoms and cognitive testing while ruling out other causes of dementia. Definitive confirmation required microscopic observation of amyloid plaques and neurofibrillary tangles in post-mortem brain tissue.

This limitation has changed dramatically over the past two decades. Modern diagnostic tools now enable physicians to detect Alzheimer's pathology in living patients with remarkable accuracy:

Biomarker Revolution

The breakthrough came from identifying specific biological markers that reflect Alzheimer's pathology:

Cerebrospinal Fluid (CSF) Analysis: Lumbar puncture can measure levels of amyloid-beta 42 (which decreases as it deposits in plaques), total tau, and phosphorylated tau (which increase as neurons degenerate). The ratio of these proteins provides strong diagnostic evidence. Research shows CSF biomarkers can detect Alzheimer's pathology 15-20 years before clinical symptoms appear.

PET Imaging: Positron emission tomography scans using specialized radiotracers can visualize amyloid plaques and tau tangles in the living brain. Amyloid PET imaging, approved by the FDA in 2012, uses compounds like florbetapir that bind to amyloid plaques, making them visible on scans. Tau PET tracers, developed more recently, can track the spread of neurofibrillary tangles through brain regions, which correlates more closely with cognitive decline than amyloid burden alone.

Blood-Based Biomarkers: The newest frontier involves simple blood tests that can detect Alzheimer's proteins. In 2024, the FDA authorized the first blood test for Alzheimer's risk assessment. Blood tests measuring plasma phosphorylated-tau (particularly p-tau217 and p-tau181) show accuracy exceeding 90% for detecting Alzheimer's pathology. These tests are revolutionizing screening and monitoring, as they're far less invasive and expensive than CSF analysis or PET scans.

Why Living Diagnosis Matters

The ability to diagnose Alzheimer's in living patients—and particularly before severe symptoms develop—has transformed research and treatment:

Clinical Trial Enrollment: Researchers can now select participants with confirmed pathology for drug trials, rather than relying on clinical symptoms that might have other causes. This has been critical for testing disease-modifying therapies like the recently approved anti-amyloid antibodies lecanemab (Leqembi) and donanemab (Kisunla).

Treatment Timing: Evidence increasingly shows that interventions work best in early disease stages. The 2025 Alzheimer's drug pipeline includes 182 trials assessing 138 agents, with biomarkers serving as primary outcomes in 27% of trials. Early diagnosis enables treatment when more neurons remain viable.

Monitoring Disease Progression: Serial biomarker measurements can track whether treatments are working at a biological level—reducing plaques, slowing tau spread—even before clinical changes become apparent. This is crucial for evaluating sleep interventions and glymphatic enhancement strategies.

The Staging Revolution

The ability to detect pathology before symptoms has led to reconceptualizing Alzheimer's as a continuum:

• Stage 1 (Preclinical): Biomarker evidence of amyloid/tau pathology with no cognitive symptoms
• Stage 2 (Prodromal/MCI): Biomarker evidence plus mild cognitive impairment
• Stage 3 (Dementia): Biomarker evidence plus significant functional impairment

This framework, introduced in revised diagnostic criteria, enables intervention at the earliest stages when sleep optimization and other preventive strategies might be most effective.

The CTE Connection: Parallel Pathways?

Chronic traumatic encephalopathy (CTE) represents a fascinating parallel to Alzheimer's disease that may illuminate shared mechanisms involving sleep and waste clearance.

What is CTE? CTE is a neurodegenerative disease associated with repetitive head impacts, famously affecting football players, boxers, and military veterans. Like Alzheimer's, it features abnormal tau protein accumulation forming neurofibrillary tangles, though the distribution pattern differs—CTE tau deposits cluster around blood vessels in characteristic patterns at the depths of cortical sulci.

The Sleep-TBI Link: Research has established strong connections between traumatic brain injury and sleep disturbances. A 2023 review in Science Progress examined how concussive injuries disrupt glymphatic function. Brain trauma can damage the delicate perivascular spaces through which cerebrospinal fluid flows, impair aquaporin-4 polarization on astrocytic endfeet, and cause inflammation that further disrupts clearance pathways.

Athletes and military personnel with histories of head trauma commonly experience sleep disorders including insomnia, sleep apnea, and circadian rhythm disturbances. These sleep problems may compound initial trauma by preventing adequate waste clearance during the critical recovery period.

Shared Mechanisms: Both Alzheimer's and CTE involve:

• Accumulation of abnormal tau protein (though in different brain regions and patterns)
• Neuroinflammation
• Vascular dysfunction
• Impaired protein clearance mechanisms
• Association with sleep disturbances

A provocative hypothesis suggests that traumatic brain injury might increase Alzheimer's risk partly by causing chronic glymphatic dysfunction. Several studies have found that moderate-to-severe TBI increases dementia risk approximately 2-4 fold. The mechanism might involve permanent damage to the brain's waste clearance infrastructure, allowing gradual accumulation of Alzheimer's-related proteins over decades.

Can Sleep Interventions Help TBI/CTE? This remains an active research question. The 2023 review on circadian therapy interventions for glymphatic dysfunction in concussion injuries proposed that treatments targeting sleep quality and timing might facilitate recovery after head trauma. These could include:

• Light therapy to stabilize circadian rhythms
• Melatonin supplementation
• Optimization of sleep positioning (some evidence suggests sleeping on one's side enhances glymphatic clearance)
• Treatment of post-traumatic sleep apnea

However, unlike Alzheimer's, CTE currently cannot be diagnosed in living patients—it still requires post-mortem brain examination. Researchers are working urgently to develop PET tracers specific for the unique tau patterns in CTE, which would enable both diagnosis and treatment monitoring. Such biomarkers would allow testing whether glymphatic enhancement strategies might slow or prevent CTE progression in high-risk individuals.

The Biomarker Challenge: While Alzheimer's now has validated blood tests, CTE biomarker development lags behind. The different distribution patterns of tau in CTE versus Alzheimer's mean that existing tau PET tracers, optimized for Alzheimer's, may not adequately visualize CTE pathology. Several research groups are developing CTE-specific tracers and blood tests, but none have yet achieved clinical validation.

The parallel between Alzheimer's and CTE underscores a broader principle: the brain's waste clearance systems, heavily dependent on sleep, may represent a common pathway through which diverse insults—aging, genetics, trauma, vascular disease—contribute to neurodegeneration. Understanding and enhancing these clearance mechanisms through sleep optimization may offer benefits across multiple neurodegenerative conditions.

---

The Glymphatic System: Discovery and Controversy

The discovery that fundamentally changed how scientists think about sleep and brain health came in 2013, when neuroscientist Maiken Nedergaard and her colleagues at the University of Rochester identified what they called the glymphatic system—a waste clearance pathway that operates primarily during sleep. Named for its dependence on glial cells and its similarity to the lymphatic system found elsewhere in the body, this network uses cerebrospinal fluid to flush interstitial fluid and dissolved waste products out of the brain.

Research published in multiple studies over the past decade has documented how slow-wave activity during non-REM sleep facilitates the synchronized mixing of cerebrospinal and interstitial fluids. The system relies heavily on aquaporin-4 water channels on astrocytic endfeet surrounding blood vessels, which help regulate fluid movement through the brain parenchyma. When functioning properly, this glymphatic clearance appears capable of removing toxic proteins, including amyloid-beta and tau, which accumulate in Alzheimer's disease.

However, the past year has seen intense scientific debate about the glymphatic hypothesis. In 2024, a study published in Nature Neuroscience challenged core aspects of the theory, reporting that mouse brains cleared dye molecules more efficiently while awake than during sleep or anesthesia—directly contradicting earlier findings. The controversy has divided the neuroscience community, with some researchers viewing the new findings as a serious challenge while others question the methodology of injecting tracers directly into brain tissue rather than cerebrospinal fluid.

Nedergaard herself has vigorously defended the glymphatic concept, arguing that the new study's techniques damage delicate brain tissue and artificially increase intracranial pressure, potentially invalidating the results. A Matters Arising commentary published in March 2025 in Nature Neuroscience continued this scientific exchange. Despite the controversy, most researchers agree that the brain has waste clearance mechanisms closely tied to sleep, even if debate continues about the precise mechanisms involved.

Sleep Architecture and Cognitive Decline

Recent research has illuminated the sophisticated relationship between sleep quality and Alzheimer's pathology. A 2024 study published in Molecular Psychiatry examined 72 older adults using magnetic resonance imaging and polysomnographic recording, finding that glymphatic function—measured by the Diffusion Tensor Image Analysis along the Perivascular Space (DTI-ALPS) index—was negatively correlated with poor sleep quality measures. Participants with better glymphatic function showed stronger structural and functional brain connectivity in regions critical for memory, including the middle temporal gyrus and parahippocampal gyrus.

The DTI-ALPS technique has emerged as a non-invasive proxy for assessing glymphatic system health in living humans. Multiple studies published in 2024 and 2025 have demonstrated reduced ALPS indices in individuals with Alzheimer's disease, including those in prodromal and preclinical stages. Perhaps most concerning, lower ALPS values predict accelerated accumulation of amyloid-beta on PET imaging, suggesting that impaired waste clearance precedes and may contribute to disease progression.

A comprehensive 2024 scoping review published in Mechanisms of Ageing and Development synthesized evidence from 70 research articles examining the glymphatic system's role in Alzheimer's-related sleep disturbances. The review identified protein aggregation following sleep deprivation, glymphatic dysfunction in sleep-disordered breathing, circadian dysregulation, and potential therapeutic interventions as key research themes. The evidence increasingly points to a bidirectional relationship: Alzheimer's pathology disrupts sleep, while poor sleep impairs the brain's ability to clear the very proteins that drive disease progression.

The Melatonin Connection

Among potential therapeutic interventions, melatonin has emerged as a compound of particular interest. This naturally occurring hormone, which regulates circadian rhythms and decreases with age, appears to offer multiple neuroprotective effects relevant to Alzheimer's disease. A comprehensive 2024 review published in Molecular Psychiatry examined melatonin's mechanisms, finding evidence that it modulates amyloid-beta production and clearance, provides antioxidant defense, regulates immune responses, and helps maintain circadian rhythms.

Research suggests melatonin may reduce amyloid burden through several pathways. It appears to inhibit beta-secretase activity, the enzyme that initiates amyloid-beta production from amyloid precursor protein. Additionally, melatonin enhances astrocytic clearance mechanisms and may promote lymphatic drainage of amyloid from the brain. In transgenic Alzheimer's mouse models, melatonin treatment showed trends toward elevated amyloid-beta levels in lymph nodes with concurrent decreases in brain amyloid.

Clinical evidence for melatonin's efficacy remains mixed but increasingly promising. A meta-analysis published in January 2025 in Alzheimer's Research & Therapy analyzed eight randomized controlled trials involving 518 participants with cognitive impairment. The pooled results indicated that melatonin significantly improved cognitive function, with effect sizes of 1.08 overall. Subgroup analyses revealed particularly strong benefits when melatonin was administered for 13-24 weeks, between 20:30 and 21:00, and in individuals with mild cognitive impairment rather than advanced dementia.

A 2025 study examining 23 Alzheimer's patients found that one month of melatonin administration improved sleep architecture, normalizing the duration and frequency of REM and slow-wave sleep phases. However, a 20-year retrospective analysis published in Alzheimer's & Dementia in 2025 noted that while sustained-release melatonin formulations showed greater efficacy trends than immediate-release versions, methodological limitations including imperfect actigraphy measurements have complicated interpretation of clinical trial results.

Sleep Apnea: A Modifiable Risk Factor

Obstructive sleep apnea represents another crucial intersection between sleep and Alzheimer's disease. This common condition, characterized by repeated breathing interruptions during sleep, affects an estimated 40% or more of institutionalized Alzheimer's patients. The mechanisms linking sleep apnea to cognitive decline include chronic intermittent hypoxia, sleep fragmentation, disrupted slow-wave sleep, and—critically—impaired glymphatic clearance.

A February 2025 study published in Thorax examined UK general practice data and found that obstructive sleep apnea was associated with a 12% increased risk of all-cause dementia and a 29% increased risk of vascular dementia. Strikingly, individuals with sleep apnea who received continuous positive airway pressure (CPAP) treatment exhibited dementia risk similar to matched controls without sleep apnea—suggesting that treatment may substantially mitigate risk.

Multiple clinical trials have demonstrated cognitive benefits from CPAP therapy in Alzheimer's patients with sleep apnea. A 2025 pilot study published in Journal of Clinical Sleep Medicine followed 21 adults with mild cognitive impairment due to Alzheimer's for 12 months. CPAP-compliant participants showed significantly slower global cognitive decline and improvements in overall cognition compared to non-users, with particular benefits in functional domains measured by the Repeatable Battery for the Assessment of Neuropsychological Status.

Earlier research found that sustained CPAP use over 13 months resulted in lasting improvements in sleep quality, mood, and slower cognitive deterioration in Alzheimer's patients. A French pilot study demonstrated that Alzheimer's patients receiving CPAP treatment showed significantly slower cognitive decline over three years compared to an untreated group. These findings have led researchers to propose CPAP as a potentially disease-modifying intervention rather than merely symptomatic treatment.

However, CPAP adherence presents challenges, particularly in cognitively impaired populations. A 2024 systematic review found that approximately 45-56% of patients with mild cognitive impairment or Alzheimer's achieved adherence (defined as four or more hours of nightly use), rates comparable to the general elderly population but still leaving many patients inadequately treated.

Clinical Trials and the Path Forward

The 2025 Alzheimer's drug development pipeline reflects growing recognition of sleep's importance, with 182 active clinical trials assessing 138 agents. While the pipeline has seen fewer agents specifically targeting circadian rhythms compared to the previous year (a decrease of two agents), sleep-related interventions remain under investigation. These include the Care2Sleep program at UC San Diego, a five-year randomized controlled trial evaluating a sleep intervention program's effects on sleep quality, health status, and inflammation in Alzheimer's patients and caregivers.

Other novel approaches are being explored. A UC San Diego trial is investigating whether time-restricted eating with 14 hours of nightly fasting can reduce Alzheimer's pathology markers and improve cognitive and sleep outcomes in patients with mild cognitive impairment or early Alzheimer's. The hypothesis is that prolonged overnight fasting may enhance metabolic processes involved in brain clearance.

Orexin receptor antagonists, a class of drugs that promote sleep, are also under investigation. A 2024 review in Drugs examined their potential for both preventing and treating Alzheimer's disease while managing associated sleep disorders. These medications may offer advantages over traditional sleep aids by more precisely targeting the brain's arousal systems.

Biomarkers and Future Diagnostics

Recent research has identified potential biomarkers linking glymphatic function to Alzheimer's risk. A January 2025 study published in Alzheimer's Research & Therapy performed proteomic analysis of cerebrospinal fluid from individuals with amnestic mild cognitive impairment who underwent serial MRI with contrast to assess glymphatic health. Seven proteins showed significant associations with glymphatic function across 78 brain regions, including NSUN6, GRAAK, and OLFML3. Pathway enrichment analysis revealed these proteins' involvement in immune response and endocytosis—processes critical for protein clearance.

These findings suggest that cerebrospinal fluid protein profiles could serve as biomarkers for glymphatic dysfunction, potentially enabling earlier identification of individuals at risk for Alzheimer's disease. Such biomarkers might also help stratify patients in clinical trials and monitor treatment responses to sleep-based interventions.

The Bigger Picture: Prevention and Treatment

The accumulating evidence suggests a multi-layered relationship between sleep and Alzheimer's disease. Poor sleep impairs glymphatic clearance, allowing toxic proteins to accumulate. These proteins damage brain regions that regulate sleep, creating a vicious cycle. Comorbid conditions like sleep apnea compound the problem through additional mechanisms including hypoxia and inflammation.

This understanding opens multiple intervention points. Optimizing sleep quality through behavioral interventions, treating sleep disorders like apnea, supplementing with melatonin or other sleep-promoting agents, and potentially developing drugs that enhance glymphatic function all represent potential strategies. Importantly, many of these interventions target modifiable risk factors, offering hope for prevention even in individuals already at genetic risk.

A 2024 bibliometric analysis published in Frontiers in Aging Neuroscience documented exponential growth in research on the glymphatic system and Alzheimer's disease, with 144 publications in 2024 compared to just 10 in 2015. This surge reflects recognition of the field's importance and suggests that understanding will continue advancing rapidly.

Looking Ahead

Despite progress, significant gaps remain. The precise mechanisms by which glymphatic dysfunction contributes to Alzheimer's pathogenesis require further elucidation. The controversy over whether sleep primarily enhances or diminishes clearance needs resolution through improved methodology and additional studies. Optimal dosing, timing, and formulations for therapeutic interventions like melatonin remain to be established through larger randomized trials.

Long-term studies are needed to determine whether sleep interventions implemented years or decades before dementia onset can truly prevent or delay disease. The field also needs better tools for non-invasively assessing glymphatic function in clinical practice, beyond research MRI techniques.

Nevertheless, the evidence increasingly supports a central role for sleep in Alzheimer's disease pathogenesis. As one researcher aptly summarized the critical nature of this connection: understanding sleep's effects on the glymphatic system and brain networks is crucial for elucidating the neurophysiological mechanisms underlying aging-related memory decline. With multiple ongoing clinical trials and continued research into mechanisms, the coming years may reveal whether optimizing sleep can indeed serve as a powerful tool in the fight against Alzheimer's disease.

---

Sources

1. Astara, K., Tsimpolis, A., Kalafatakis, K., et al. (2024). Sleep disorders and Alzheimer's disease pathophysiology: The role of the Glymphatic System. A scoping review. Mechanisms of Ageing and Development, 217, 111899. https://doi.org/10.1016/j.mad.2023.111899

2. Cullell, N., Caruana, G., Elias-Mas, A., et al. (2025). Glymphatic system clearance and Alzheimer's disease risk: a CSF proteome-wide study. Alzheimer's Research & Therapy, 17, 31. https://doi.org/10.1186/s13195-024-01612-7

3. Ray, N. J., Cullell, N., Clark, O., et al. (2024). Glymphatic system health in early Alzheimer's disease and its relationship to sleep, cognition and CSF biomarkers. bioRxiv. https://doi.org/10.1101/2024.10.14.618324

4. Li, H., Yao, Q., Huang, X., Yang, X., & Yu, C. (2024). The role and mechanism of Aβ clearance dysfunction in the glymphatic system in Alzheimer's disease comorbidity. Frontiers in Neurology, 15, 1474439. https://doi.org/10.3389/fneur.2024.1474439

5. Ma, J., Chen, M., Liu, G. H., et al. (2024). Effects of sleep on the glymphatic functioning and multimodal human brain network affecting memory in older adults. Molecular Psychiatry, 30, 1717-1729. https://doi.org/10.1038/s41380-024-02778-0

6. Corbali, O., & Levey, A. I. (2025). Glymphatic system in neurological disorders and implications for brain health. Frontiers in Aging Neuroscience, 17, 1579373. https://pmc.ncbi.nlm.nih.gov/articles/PMC11835678/

7. Liu, S., Zhuang, L., & Li, X. (2025). Research hotspots and frontiers of glymphatic system and Alzheimer's disease: a bibliometrics analysis. Frontiers in Aging Neuroscience, 17, 1579373. https://doi.org/10.3389/fnagi.2025.1579373

8. Cummings, J., Apostolova, L., Rabinovici, G. D., et al. (2025). Alzheimer's disease drug development pipeline: 2025. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(2), e12571. https://doi.org/10.1002/trc2.70098

9. Zhang, Z., Xue, P., Bendlin, B. B., et al. (2024). Melatonin: A potential nighttime guardian against Alzheimer's. Molecular Psychiatry, 30, 237-250. https://doi.org/10.1038/s41380-024-02691-6

10. Sushko, I., et al. (2025). Melatonin to treat sleep disturbances in patients with Alzheimer's disease. Alzheimer's & Dementia, 20. https://doi.org/10.1002/alz.083775

11. Malhotra, R., et al. (2025). Reevaluating Melatonin's Efficacy in Alzheimer's Disease: A 20th-Anniversary Updated Literature Review of Sleep Disturbances and Treatment Trials. Alzheimer's & Dementia, 20. https://doi.org/10.1002/alz.095541

12. Leung, L. Y. L., Tam, H. L., Asiamah, N., et al. (2025). Effect of melatonin on cognitive function in adults with cognitive impairment: a multi-dimensional meta-analysis of randomized trials. Alzheimer's Research & Therapy, 17, 238. https://doi.org/10.1186/s13195-025-01881-w

13. Cardinali, D. P., Vigo, D. E., Olivar, N., Vidal, M. F., & Brusco, L. I. (2014). Melatonin Therapy in Patients with Alzheimer's Disease. Antioxidants, 3(2), 245-277. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665493/

14. Oliver, C., Li, H., Biswas, B., et al. (2024). A systematic review on adherence to continuous positive airway pressure (CPAP) treatment for obstructive sleep apnoea (OSA) in individuals with mild cognitive impairment and Alzheimer's disease dementia. Sleep Medicine Reviews, 73, 101869. https://doi.org/10.1016/j.smrv.2023.101869

15. Martins, R., Andrade, A. G., & Garner, D. (2019). The relationship between Obstructive Sleep Apnea and Alzheimer's Disease. Journal of Alzheimer's Disease, 64(s1), S255-S270. https://pmc.ncbi.nlm.nih.gov/articles/PMC6542637/

16. Cooke, J. R., Ayalon, L., Palmer, B. W., et al. (2009). Sustained use of CPAP slows deterioration of cognition, sleep, and mood in patients with Alzheimer's disease and obstructive sleep apnea: a preliminary study. Journal of Clinical Sleep Medicine, 5(4), 305-309. https://pmc.ncbi.nlm.nih.gov/articles/PMC2725246/

17. Wang, J., Subramanian, A., Cockburn, N., et al. (2025). Obstructive sleep apnoea syndrome and future risk of dementia among individuals managed in UK general practice. Thorax, 80(3), 167-174. https://doi.org/10.1136/thorax-2024-221810

18. García-Alberca, J. M., et al. (2025). A Pilot Study: The Effect of CPAP Intervention on Sleep Architecture and Cognition in Alzheimer's Disease Patients with Obstructive Sleep Apnea. Brain Sciences, 15(9). https://pmc.ncbi.nlm.nih.gov/articles/PMC12472331/

19. Carpi, M., Mercuri, N. B., & Liguori, C. (2024). Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer's Disease and Associated Sleep Disorders. Drugs, 84(11), 1365-1378. https://doi.org/10.1007/s40265-024-02096-3

20. Mestre, H., Mori, Y., & Nedergaard, M. (2020). The brain's glymphatic system: current controversies. Trends in Neurosciences, 43(7), 458-466. https://doi.org/10.1016/j.tins.2020.04.003

21. Hauglund, N. L., et al. (2025). Meningeal lymphatics regulate brain tissue clearance during sleep. Cell, 188, 606-622.

22. Miao, A., et al. (2024). Brain clearance is reduced during sleep. Nature Neuroscience, 27, 1046-1050.

23. Abbott, N. J., Pizzo, M. E., Preston, J. E., et al. (2018). The role of brain barriers in fluid movement in the CNS: is there a 'glymphatic' system? Acta Neuropathologica, 135, 387-407.

24. Jessen, N. A., Munk, A. S., Lundgaard, I., & Nedergaard, M. (2015). The Glymphatic System: A Beginner's Guide. Neurochemical Research, 40(12), 2583-2599.

25. Xiao, D., & Zhang, C. (2024). Current therapeutics for Alzheimer's disease and clinical trials. Exploration of Neuroscience, 3, 255-271. https://www.explorationpub.com/Journals/en/Article/100648

26. Kureshi, S., Stowe, C., Francis, J., & Djalilian, H. (2023). Circadian therapy interventions for glymphatic dysfunction in concussions injuries: A narrative review. Science Progress, 106(3). https://doi.org/10.1177/00368504231189536

27. Jack, C. R., Bennett, D. A., Blennow, K., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia, 14(4), 535-562.

28. Hansson, O., Edelmayer, R. M., Boxer, A. L., et al. (2022). The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimer's & Dementia, 18(12), 2669-2686.